Research and Development Investment: Dr. Reddy's Laboratories Limited vs Perrigo Company plc

Dr. Reddy's R&D investment dwarfs Perrigo's over a decade.

__timestampDr. Reddy's Laboratories LimitedPerrigo Company plc
Wednesday, January 1, 201412402000000152500000
Thursday, January 1, 201517449000000187800000
Friday, January 1, 201617834000000184000000
Sunday, January 1, 201719551000000167700000
Monday, January 1, 201818265000000218600000
Tuesday, January 1, 201915607000000187400000
Wednesday, January 1, 202015410000000177700000
Friday, January 1, 202116541000000122000000
Saturday, January 1, 202217482000000123100000
Sunday, January 1, 202319381000000122500000
Monday, January 1, 202422873000000
Loading chart...

Unleashing insights

A Decade of R&D Investment: Dr. Reddy's vs. Perrigo

In the competitive landscape of pharmaceuticals, research and development (R&D) investment is a key driver of innovation and growth. Over the past decade, Dr. Reddy's Laboratories Limited has consistently outpaced Perrigo Company plc in R&D spending. From 2014 to 2023, Dr. Reddy's increased its R&D investment by approximately 84%, peaking in 2023. In contrast, Perrigo's R&D expenses remained relatively stable, with a slight decline observed in recent years.

Dr. Reddy's commitment to innovation is evident, with its R&D expenses reaching nearly 20 times that of Perrigo's in 2023. This significant investment underscores Dr. Reddy's strategic focus on developing new products and enhancing existing ones. Meanwhile, Perrigo's steady R&D spending suggests a more conservative approach, potentially focusing on optimizing current offerings. The data for 2024 is incomplete, highlighting the need for ongoing analysis to understand future trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025